Allergy and Infectious Diseases Research
CFDA 93.855 · Federal Grants & Funding
Total Funding
$36.37B
Awards
13K
Recipients
1K
States
52
Last Updated
Mar 20, 2026
Yearly Funding Trend
| Fiscal Year | Obligations | Awards | YoY Change |
|---|---|---|---|
| 2024 | $31.19B | 9K | |
| 2025 | $4.54B | 3K | -85.4% |
| 2026 | $637.1M | 479 | -86.0% |
Award Type Mix
| Type | Obligations | Awards |
|---|---|---|
| $0 | 0 | |
| $0 | 0 |
Top 50 Awards under CFDA 93.855
Largest individual obligations for Allergy and Infectious Diseases Research.
| Award | Recipient | Awarding Agency | Place | FY | Obligation |
|---|---|---|---|---|---|
ASST_NON_UM1AI068614_075 HIV VACCINES CLINICAL TRIALS NETWORK LEADERSHIP AND OPERATIONS CENTER - THIS PROPOSAL OUTLINES THE SCIENTIFIC AGENDA OF THE LEADERSHIP AND OPERATIONS CENTER OF THE HIV VACCINE TRI… | FRED HUTCHINSON CANCER CENTER Washington | Department of Health and Human Services National Institutes of Health | SEATTLE, WA-07 | 2024 | $1,062,954,652 |
ASST_NON_UM1AI068636_075 COVPN 3502 / ACTIV-2/A5401 - ABSTRACT A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIE… | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL North Carolina | Department of Health and Human Services National Institutes of Health | CHAPEL HILL, NC-04 | 2024 | $996,069,592 |
ASST_NON_UM1AI068619_075 HIV PREVENTION TRIALS NETWORK LEADERSHIP AND OPERATIONS CENTER - PROJECT SUMMARY THE OVERARCHING GOAL OF THE HIV PREVENTION TRIALS NETWORK (HPTN) IS TO IDENTIFY ACCEPTABLE, FEASIB… | FAMILY HEALTH INTERNATIONAL North Carolina | Department of Health and Human Services National Institutes of Health | DURHAM, NC-04 | 2024 | $700,632,881 |
ASST_NON_UM1AI109565_075 IMMUNE TOLERANCE NETWORK - PROJECT SUMMARY / ABSTRACT THE MISSION OF THE ITN IS TO ADVANCE THE CLINICAL APPLICATION OF IMMUNE TOLERANCE BY PERFORMING HIGH QUALITY CLINICAL TRIALS… | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON Washington | Department of Health and Human Services National Institutes of Health | SEATTLE, WA-07 | 2024 | $438,527,853 |
ASST_NON_UM1AI068635_075 SDMC: HIV VACCINE TRIALS NETWORK - PROJECT SUMMARY/ABSTRACT THIS APPLICATION PROPOSES TO CONTINUE AS THE STATISTICAL AND DATA MANAGEMENT CENTER (SDMC) FOR THE HIV VACCINE TRIALS N… | FRED HUTCHINSON CANCER CENTER Washington | Department of Health and Human Services National Institutes of Health | SEATTLE, WA-07 | 2024 | $368,129,707 |
ASST_NON_UM1AI068632_075 IMPAACT LEADERSHIP GROUP - THE OVER-ARCHING GOAL OF THE INTERNATIONAL MATERNAL PEDIATRIC ADOLESCENT AIDS CLINICAL TRIALS (IMPAACT) NETWORK IS TO IDENTIFY SAFE, ACCEPTABLE, FEASIBL… | THE JOHNS HOPKINS UNIVERSITY Maryland | Department of Health and Human Services National Institutes of Health | BALTIMORE, MD-07 | 2024 | $269,964,834 |
ASST_NON_UM1AI068634_075 STATISTICAL AND DATA MANAGEMENT CENTER (SDMC), ADVANCING CLINICAL THERAPEUTICS GLOBALLY FOR HIV/AIDS AND OTHER INFECTIONS (ACTG) - PROJECT SUMMARY/ABSTRACT THIS APPLICATION REQUES… | PRESIDENT AND FELLOWS OF HARVARD COLLEGE Massachusetts | Department of Health and Human Services National Institutes of Health | BOSTON, MA-07 | 2024 | $236,504,084 |
ASST_NON_UM1AI144462_075 CONSORTIUM FOR HIV/AIDS VACCINE DEVELOPMENT - PROJECT SUMMARY/ABSTRACT (30 LINES) THE OVERARCHING GOAL OF THIS CHAVD IS TO DEVELOP A SEQUENTIAL HIV VACCINE REGIMEN THAT INDUCES SU… | SCRIPPS RESEARCH INSTITUTE California | Department of Health and Human Services National Institutes of Health | LA JOLLA, CA-50 | 2024 | $201,437,825 |
ASST_NON_UM2AI117870_075 RHO FEDERAL SYSTEMS DIVISION, INC. NIAID DAIT SACCC - THIS PROJECT IS A ONE-YEAR EXTENSION OF THE CONSOLIDATED DAIT STATISTICAL AND CLINICAL COORDINATING CENTER (DAIT SACCC). THE… | RHO FEDERAL SYSTEMS DIVISION INC North Carolina | Department of Health and Human Services National Institutes of Health | DURHAM, NC-04 | 2024 | $200,221,259 |
ASST_NON_UM1AI068617_075 SDMC: HIV PREVENTION TRIALS NETWORK - PROJECT SUMMARY/ABSTRACT THIS APPLICATION TO RFA-AI-19-002 IS TO CONTINUE AS THE STATISTICAL AND DATA MANAGEMENT CENTER (SDMC) FOR THE HIV PR… | FRED HUTCHINSON CANCER CENTER Washington | Department of Health and Human Services National Institutes of Health | SEATTLE, WA-07 | 2024 | $195,693,448 |
ASST_NON_UM1AI144371_075 INDUCTION OF PROTECTIVE ANTIBODIES FOR HIV VACCINE DEVELOPMENT - THIS CONSORTIUM FOR HIV/AIDS VACCINE DEVELOPMENT (CHAVD) WILL APPLY STATE-OF-THE-ART TECHNOLOGIES AND IMMUNOLOGIC… | DUKE UNIVERSITY North Carolina | Department of Health and Human Services National Institutes of Health | DURHAM, NC-04 | 2024 | $190,396,050 |
ASST_NON_UC7AI094660_075 LIMITED COMPETITION: NATIONAL BIOCONTAINMENT LABORATORIES (NBLS) OPERATIONS SUPPORT (UC7 CLINICAL TRIAL NOT ALLOWED) - PROJECT SUMMARY/ABSTRACT THE GOAL OF THIS PROJECT IS TO MAIN… | UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON Texas | Department of Health and Human Services National Institutes of Health | GALVESTON, TX-14 | 2024 | $185,816,804 |
ASST_NON_UM1AI104681_075 ANTIBACTERIAL RESISTANCE LEADERSHIP GROUP (ARLG) - OUR GOAL IS TO CONTINUE TO ADVANCE THE SUCCESSFUL, MULTIDISCIPLINARY RESEARCH AGENDA OF THE ANTIBACTERIAL RESISTANCE LEADERSHIP… | DUKE UNIVERSITY North Carolina | Department of Health and Human Services National Institutes of Health | DURHAM, NC-04 | 2024 | $180,737,624 |
ASST_NON_P51OD011107_075 CALIFORNIA NATIONAL PRIMATE RESEARCH CENTER - OVERALL: CALIFORNIA NATIONAL PRIMATE RESEARCH CENTER ABSTRACT THE CALIFORNIA NATIONAL PRIMATE RESEARCH CENTER (CNPRC), LOCATED AT THE… | UNIVERSITY OF CALIFORNIA, DAVIS California | Department of Health and Human Services National Institutes of Health | DAVIS, CA-04 | 2024 | $179,413,083 |
ASST_NON_UM1AI068616_075 SDMC - IMPAACT LEADERSHIP GROUP - PROJECT SUMMARY/ABSTRACT THIS APPLICATION REQUESTS RENEWAL OF FUNDING TO SERVE AS THE STATISTICAL AND DATA MANAGEMENT CENTER OF THE INTERNATIONAL… | PRESIDENT AND FELLOWS OF HARVARD COLLEGE Massachusetts | Department of Health and Human Services National Institutes of Health | BOSTON, MA-07 | 2024 | $151,627,670 |
ASST_NON_P51OD011106_075 WISCONSIN NATIONAL PRIMATE RESEARCH CENTER SUPPORT - SUMMARY/ABSTRACT: THE WISCONSIN NATIONAL PRIMATE RESEARCH CENTER (WNPRC) IS ONE OF SEVEN FEDERALLY SUPPORTED NATIONAL PRIMATE… | UNIVERSITY OF WISCONSIN SYSTEM Wisconsin | Department of Health and Human Services National Institutes of Health | MADISON, WI-02 | 2024 | $140,230,629 |
ASST_NON_U24TR001608_075 ACTIV-6 - ABSTRACT SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) IS A NOVEL BETACORONAVIRUS THAT FIRST EMERGED IN DECEMBER 2019 AND HAS SINCE CAUSED A GLOBAL PANDEM… | DUKE UNIVERSITY North Carolina | Department of Health and Human Services National Institutes of Health | DURHAM, NC-04 | 2024 | $139,753,636 |
ASST_NON_UC7AI095321_075 NATIONAL EMERGING INFECTIOUS DISEASES LABORATORIES OPERATIONS - OVERALL ABSTRACT THE NATIONAL BIOCONTAINMENT LABORATORY (NBL) AT BOSTON UNIVERSITY (BU) IS KNOWN AS THE NATIONAL EM… | TRUSTEES OF BOSTON UNIVERSITY Massachusetts | Department of Health and Human Services National Institutes of Health | BOSTON, MA-07 | 2024 | $136,265,880 |
ASST_NON_P51OD011104_075 TULANE NATIONAL PRIMATE RESEARCH CENTER - PROJECT SUMMARY – OVERALL THE TULANE NATIONAL PRIMATE RESEARCH CENTER (TNPRC) IS AFFILIATED WITH TULANE UNIVERSITY OF LOUISIANA AND WAS D… | THE ADMINISTRATORS OF TULANE EDUCATIONAL FUND Louisiana | Department of Health and Human Services National Institutes of Health | LA-90 | 2024 | $132,964,607 |
ASST_NON_UM1AI106701_075 AIDS CLINICAL TRIAL GROUP LABORATORY CENTER - ABSTRACT THE AIDS CLINICAL TRIALS GROUP (ACTG) HAS BEEN AT THE FOREFRONT OF CLINICAL RESEARCH TO ADVANCE HIV THERAPEUTICS AND IMPROVE… | UNIVERSITY OF CALIFORNIA, LOS ANGELES California | Department of Health and Human Services National Institutes of Health | LOS ANGELES, CA-36 | 2024 | $111,797,794 |
ASST_NON_UM1AI068613_075 LC: HIV PREVENTION TRIALS NETWORK - PROJECT SUMMARY WITH 20 YEARS OF EXPERIENCE AND AN OUTSTANDING RECORD OF PERFORMANCE, THE HIV PREVENTION TRIALS NETWORK (HPTN) LABORATORY CENTE… | THE JOHNS HOPKINS UNIVERSITY Maryland | Department of Health and Human Services National Institutes of Health | BALTIMORE, MD-07 | 2024 | $94,989,799 |
ASST_NON_U19AI171399_075 AI-DRIVEN STRUCTURE-ENABLED ANTIVIRAL PLATFORM (ASAP) - PROJECT SUMMARY/ABSTRACT - OVERALL SARS-COV-2 CONTINUES TO CAUSE SEVERE MORBIDITY AND MORTALITY IN THE ONGOING PANDEMIC. FU… | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH New York | Department of Health and Human Services National Institutes of Health | NY-90 | 2024 | $89,845,851 |
ASST_NON_R24AI067039_075 CFAR NETWORK OF INTEGRATED CLINICAL SYSTEMS (CNICS) - PROJECT SUMMARY / ABSTRACT MODERN ANTIRETROVIRAL TREATMENTS ALTER THE PROGRESSION OF DISEASE, ENABLING THE MAJORITY OF HIV+ I… | UNIVERSITY OF ALABAMA AT BIRMINGHAM Alabama | Department of Health and Human Services National Institutes of Health | BIRMINGHAM, AL-07 | 2024 | $85,001,250 |
ASST_NON_UM1AI148684_075 LEADERSHIP GROUP FOR THE INFECTIOUS DISEASES CLINICAL RESEARCH CONSORTIUM (IDCRCLG) - THIS INFECTIOUS DISEASES CLINICAL RESEARCH CONSORTIUM LEADERSHIP GROUP (IDCRCLG OR LG) IS A N… | EMORY UNIVERSITY Georgia | Department of Health and Human Services National Institutes of Health | ATLANTA, GA-05 | 2024 | $72,987,380 |
ASST_NON_UM1AI069436_075 UZ-UCSF CTU - PROJECT SUMMARY/ABSTRACT FOR OVER 2 DECADES THE UNIVERSITY OF ZIMBABWE-UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CLINICAL TRIALS UNIT (UZ- UCSF CTU) HAS CONTINUOUSLY C… | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE California | Department of Health and Human Services National Institutes of Health | SAN FRANCISCO, CA-11 | 2024 | $71,884,141 |
ASST_NON_U19AI057229_075 UNDERSTANDING INFLUENZA AND SARS-COV-2 VACCINE RESPONSES, IN VIVO AND IN VITRO - PROJECT SUMMARY INFLUENZA AND SARS-COV-2 ARE RESPIRATORY VIRUSES THAT REPRESENT A CONTINUAL THREAT… | THE LELAND STANFORD JUNIOR UNIVERSITY California | Department of Health and Human Services National Institutes of Health | CA-90 | 2024 | $69,450,026 |
ASST_NON_U19AI171421_075 DEVELOPMENT OF OUTPATIENT ANTIVIRAL COCKTAILS AGAINST SARS-COV-2 AND OTHER POTENTIAL PANDEMIC RNA VIRUSES. - ABSTRACT: THE OVERALL PLATFORM AND OBJECTIVE OF THE STANFORD AVIDD CEN… | THE LELAND STANFORD JUNIOR UNIVERSITY California | Department of Health and Human Services National Institutes of Health | STANFORD, CA-16 | 2025 | $69,058,677 |
ASST_NON_UM1AI069423_075 UNIVERSITY OF NORTH CAROLINA GLOBAL HIV PREVENTION AND TREATMENT CLINICAL TRIALS UNIT - THE UNIVERSITY OF NORTH CAROLINA (UNC) GLOBAL HIV PREVENTION AND TREATMENT CLINICAL TRIALS… | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL North Carolina | Department of Health and Human Services National Institutes of Health | CHAPEL HILL, NC-04 | 2024 | $68,990,113 |
ASST_NON_U19AI171443_075 CENTER FOR ANTIVIRAL MEDICINES & PANDEMIC PREPAREDNESS (CAMPP) - SUMMARY THE ONGOING COVID-19 PANDEMIC HAS BROUGHT TO LIGHT AN URGENT NEED TO ENHANCE THE THERAPEUTIC PREPAREDNESS… | SCRIPPS RESEARCH INSTITUTE California | Department of Health and Human Services National Institutes of Health | CA-90 | 2024 | $67,624,156 |
ASST_NON_U19AI171110_075 QCRG PANDEMIC RESPONSE PROGRAM - QCRG PANDEMIC RESPONSE PROGRAM OVERALL SUMMARY THE QCRG (QUANTITATIVE BIOSCIENCES INSTITUTE CORONAVIRUS RESEARCH GROUP) PANDEMIC RESPONSE PROGRAM… | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE California | Department of Health and Human Services National Institutes of Health | CA-90 | 2025 | $67,452,049 |
ASST_NON_U19AI110483_075 REGULATION OF B CELL RESPONSES IN SLE AND OTHER AUTOIMMUNE DISEASES - THE OVERARCHING OBJECTIVE OF THE EMORY AUTOIMMUNITY CENTER OF EXCELLENCE (ACE) U19 IS TO DECIPHER THE MOLECUL… | EMORY UNIVERSITY Georgia | Department of Health and Human Services National Institutes of Health | GA-90 | 2024 | $67,380,362 |
ASST_NON_U19AI171954_075 MIDWEST AVIDD CENTER - OVERALL – MIDWEST AVIDD CENTER ABSTRACT THE MIDWEST ANTI-VIRAL DRUG DEVELOPMENT (AVIDD) CENTER WAS FORMALIZED AS A DIRECT RESPONSE TO NIAID U19 RFA RFA-AI-… | REGENTS OF THE UNIVERSITY OF MINNESOTA Minnesota | Department of Health and Human Services National Institutes of Health | MN-90 | 2025 | $66,881,972 |
ASST_NON_U19AI110818_075 ADVANCING GENOMIC, TRANSCRIPTOMIC AND FUNCTIONAL APPROACHES TO COMBAT GLOBALLY IMPORTANT AND EMERGING PATHOGENS - INFECTIOUS DISEASES REMAIN AN IMPORTANT GLOBAL THREAT DESPITE THE… | THE BROAD INSTITUTE, INC Massachusetts | Department of Health and Human Services National Institutes of Health | MA-90 | 2024 | $66,465,350 |
ASST_NON_U19AI057266_075 VACCINE AND INFECTION INDUCED IMMUNITY IN THE YOUNG AND AGED - THE OVERARCHING GOAL OF OUR CCHI APPLICATION ON “VACCINE AND INFECTION INDUCED IMMUNITY IN THE YOUNG AND AGED” IS TO… | EMORY UNIVERSITY Georgia | Department of Health and Human Services National Institutes of Health | ATLANTA, GA-05 | 2024 | $65,998,262 |
ASST_NON_U19AI171292_075 RAPIDLY EMERGING ANTIVIRAL DRUG DEVELOPMENT INITIATIVE- AVIDD CENTER (READDI-AC) - PROGRAM SUMMARY/ABSTRACT EMERGING VIRUSES ARISE SUDDENLY AND CAUSE CONSIDERABLE MORBIDITY AND MO… | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL North Carolina | Department of Health and Human Services National Institutes of Health | NC-90 | 2024 | $65,483,194 |
ASST_NON_U19AI171401_075 METROPOLITAN ANTIVIRAL DRUG ACCELERATOR - ABSTRACT THE COVID-19 PANDEMIC CAUSED BY SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) HAS RESULTED IN MILLIONS OF DEATHS… | HMH HOSPITALS CORPORATION New Jersey | Department of Health and Human Services National Institutes of Health | NJ-90 | 2025 | $65,141,731 |
ASST_NON_P30AI094189_075 THE JOHNS HOPKINS CENTER FOR AIDS RESEARCH (JHU CFAR) - THE MISSION OF THE CFAR IS TO CATALYZE, SUPPORT, AND SUSTAIN THE CONTINUATION OF INNOVATIVE RESEARCH TO END THE HIV EPIDEMI… | THE JOHNS HOPKINS UNIVERSITY Maryland | Department of Health and Human Services National Institutes of Health | BALTIMORE, MD-07 | 2024 | $60,907,061 |
ASST_NON_UM2AI130836_075 NEW HORIZONS IN THE PREVENTION AND TREATMENT OF FOOD ALLERGY - SUMMARY THE OVERARCHING GOAL OF THE RESEARCH AGENDA DESCRIBED IN THIS APPLICATION IS TO POSITION COFAR AS THE INTERN… | THE JOHNS HOPKINS UNIVERSITY Maryland | Department of Health and Human Services National Institutes of Health | BALTIMORE, MD-07 | 2024 | $60,438,956 |
ASST_NON_U01AI069918_075 NORTH AMERICAN AIDS COHORTS ON COLLABORATION AND DESIGN (NAACCORD) - (NO MORE THAN 30 LINES) THE NORTH AMERICAN AIDS COHORT COLLABORATION ON RESEARCH AND DESIGN (NA-ACCORD) HAS RE… | THE JOHNS HOPKINS UNIVERSITY Maryland | Department of Health and Human Services National Institutes of Health | MD-90 | 2024 | $57,926,840 |
ASST_NON_U01AI063594_075 CTOT: BIOMARKER GUIDED CNI SUBSTITUTION IN KIDNEY TRANSPLANTATION - IN THIS COMPETITIVE RENEWAL OF A CLINICAL TRIALS IN ORGAN TRANSPLANTATION CONSORTIUM FUNDED FOR >16 YEARS, WE W… | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI New York | Department of Health and Human Services National Institutes of Health | NY-90 | 2025 | $56,879,122 |
ASST_NON_U19AI171413_075 UTMB-NOVARTIS ALLIANCE FOR PANDEMIC PREPAREDNESS - OVERALL – ABSTRACT PANDEMIC PREVENTION AND PREPAREDNESS IS A MAJOR SCIENTIFIC AND SOCIETAL PRIORITY THAT REQUIRES SUSTAINED AND… | UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON Texas | Department of Health and Human Services National Institutes of Health | TX-90 | 2025 | $56,163,625 |
ASST_NON_UM1AI069412_075 BOSTON HIV CTU - THE BOSTON/JACKSON/PROVIDENCE HIV CLINICAL TRIALS UNIT (BJP HIV CTU) WILL CONDUCT CLINICAL TRIALS TO ADDRESS RESEARCH PRIORITIES OF THREE NIAID HIV/AIDS CLINICAL… | BRIGHAM & WOMENS HOSPITAL INC Massachusetts | Department of Health and Human Services National Institutes of Health | BOSTON, MA-07 | 2024 | $54,691,007 |
ASST_NON_P01AI045897_075 A TOLERANCE APPROACH TO XENOTRANSPLANTATION - THIS PROPOSAL REPRESENTS THE RENEWAL OF A HIGHLY INTEGRATED PPG AIMED AT INDUCTION OF TOLERANCE TO PORCINE ORGANS TRANSPLANTED INTO P… | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK New York | Department of Health and Human Services National Institutes of Health | NEW YORK, NY-13 | 2024 | $53,595,606 |
ASST_NON_UM1AI124377_075 CONSORTIA FOR INNOVATIVE AIDS RESEARCH IN NONHUMAN PRIMATES - SUMMARY THE OVERALL GOAL OF OUR CONSORTIUM IS TO ELUCIDATE THE IMMUNOLOGIC MECHANISMS OF LEADING HIV-1 PROPHYLACTIC V… | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. Massachusetts | Department of Health and Human Services National Institutes of Health | BOSTON, MA-07 | 2024 | $52,853,725 |
ASST_NON_U19AI171403_075 ANTIVIRAL COUNTERMEASURES DEVELOPMENT CENTER (AC/DC) - THE ANTIVIRAL COUNTERMEASURES DEVELOPMENT CENTER (AC/DC) WILL TARGET PATHOGENS IN FIVE FAMILIES OF RNA VIRUSES WITH SIGNIFIC… | EMORY UNIVERSITY Georgia | Department of Health and Human Services National Institutes of Health | GA-90 | 2024 | $51,914,880 |
ASST_NON_U19AI100627_075 SYSTEMS APPROACH TO IMMUNITY AND INFLAMMATION - SUMMARY THE INNATE IMMUNE RESPONSE IS A DOUBLE-EDGED SWORD; IT IS ABSOLUTELY REQUIRED FOR HOST DEFENSE, BUT UNREGULATED, CAUSES INF… | SCRIPPS RESEARCH INSTITUTE California | Department of Health and Human Services National Institutes of Health | LA JOLLA, CA-50 | 2024 | $49,114,253 |
ASST_NON_UM1AI069424_075 UCLA AIDS PREVENTION AND TREATMENT CLINICAL TRIALS UNIT - PROJECT SUMMARY THE OVERARCHING GOAL OF THE UCLA AIDS PREVENTION AND TREATMENT CLINICAL TRIALS UNIT (CTU) IS TO MAKE SIGN… | UNIVERSITY OF CALIFORNIA, LOS ANGELES California | Department of Health and Human Services National Institutes of Health | LOS ANGELES, CA-37 | 2024 | $49,013,657 |
ASST_NON_UM1AI148689_075 IMPLEMENTING VACCINE AND TREATMENT EVALUATION UNIT (VTEU) CLINICAL SITE - PROJECT SUMMARY/ABSTRACT THE UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE (UMSOM) CENTER FOR VACCINE DEVELOP… | UNIVERSITY OF MARYLAND, BALTIMORE Maryland | Department of Health and Human Services National Institutes of Health | BALTIMORE, MD-07 | 2024 | $48,631,108 |
ASST_NON_UM1AI069432_075 UCSD COLLABORATIVE CLINICAL TRIALS UNIT - ABSTRACT THE UCSD COLLABORATIVE CLINICAL TRIALS UNIT (CTU) WILL BRING TOGETHER SEVEN DYNAMIC U.S. AND INTERNATIONAL CLINICAL RESEARCH SIT… | UNIVERSITY OF CALIFORNIA, SAN DIEGO California | Department of Health and Human Services National Institutes of Health | SAN DIEGO, CA-50 | 2024 | $48,283,771 |
ASST_NON_U19AI181960_075 FLAVIVIRUS AND ALPHAVIRUS REVAMPP (FLARE) - SUMMARY. THE FLAVIVIRUS AND ALPHAVIRUS REVAMPP (FLARE) CENTER WILL DEVELOP AND OPTIMIZE PROTEIN NANOPARTICLE, VIRION-BASED, AND MRNA VA… | WASHINGTON UNIVERSITY, THE Missouri | Department of Health and Human Services National Institutes of Health | SAINT LOUIS, MO-01 | 2024 | $46,715,173 |
Top 50 awards shown, ranked by obligated amount. Dates reflect performance period; last-modified dates match USAspending.gov. Complete listings include all transaction history going back to FY2024.
Spending by State
| State | Funding | Awards |
|---|---|---|
| California | $4.88B | 2K |
| North Carolina | $3.87B | 566 |
| Massachusetts | $3.63B | 1K |
| Washington | $3.36B | 547 |
| New York | $3.06B | 1K |
| Maryland | $2.14B | 676 |
| Pennsylvania | $1.63B | 793 |
| Texas | $1.62B | 702 |
| Georgia | $1.31B | 438 |
| Illinois | $838.5M | 443 |
| Tennessee | $780.1M | 286 |
| Missouri | $764.3M | 357 |
| Ohio | $689.4M | 374 |
| Connecticut | $617.8M | 294 |
| Wisconsin | $602.0M | 221 |
| New Jersey | $533.2M | 201 |
| Minnesota | $488.7M | 231 |
| Colorado | $475.8M | 339 |
| Alabama | $446.4M | 157 |
| Michigan | $443.0M | 234 |
| Florida | $427.6M | 253 |
| Virginia | $346.8M | 234 |
| Louisiana | $334.2M | 102 |
| Oregon | $285.3M | 120 |
| Indiana | $273.1M | 178 |
| Iowa | $238.4M | 140 |
| Arizona | $192.5M | 101 |
| Utah | $178.1M | 108 |
| Oklahoma | $155.1M | 73 |
| District of Columbia | $139.5M | 74 |
| Rhode Island | $129.2M | 115 |
| Nebraska | $118.9M | 60 |
| New Hampshire | $108.9M | 62 |
| Kentucky | $108.5M | 74 |
| New Mexico | $98.3M | 38 |
| South Carolina | $87.8M | 70 |
| Vermont | $55.6M | 36 |
| Kansas | $55.3M | 55 |
| Arkansas | $43.7M | 45 |
| Nevada | $29.0M | 22 |
| Montana | $28.6M | 27 |
| West Virginia | $21.9M | 14 |
| Hawaii | $21.8M | 14 |
| Idaho | $15.9M | 14 |
| Puerto Rico | $11.9M | 4 |
| Mississippi | $9.6M | 17 |
| North Dakota | $9.1M | 12 |
| Alaska | $4.4M | 2 |
| Delaware | $4.2M | 7 |
| Wyoming | $4.0M | 4 |
| South Dakota | $2.3M | 2 |
| Maine | $1.3M | 2 |
Top Recipients
Agencies Administering This Program
Source: USAspending.gov · All Programs